Basic Information
MAREVAN TABLET 5 mg (NEW ZEALAND)
TABLET
Regulatory Information
SIN08147P
May 5, 1995
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XB01AA03
Company Information
Active Ingredients
Strength: 5 mg
Detailed Information
Contraindications
**Contraindications** Warfarin is contraindicated in: - Known hypersensitivity to warfarin or to any of the excipients - Haemorrhagic stroke - Clinical significant bleeding - Within 72 hours of major surgery with risk of severe bleeding - Within 48 hours postpartum - Pregnancy (first and third trimesters, see section _Pregnancy and Lactation_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Concomitant use of fibrinolytic drugs such as streptokinase and alteplase and drugs where interactions may lead to a significantly increased risk of bleeding (see section _Interactions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) - Bacterial endocarditis - Severe hepatic or renal disease - Actual or potential haemorrhagic conditions, e.g. haemophilia, hypertension, gastrointestinal ulcerations, threatened abortion.
Indication Information
**Indications** For: - Prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation. - Prophylaxis of thromboembolism after insertion of prosthetic heart valves. - Prophylaxis and treatment of venous thrombosis and pulmonary embolism. - Transient attacks of cerebral ischaemia.